Invitation to Press Briefing – 5 March 2025
In connection with the publication of results from two independent research studies on ColdZyme, Enzymatica AB invites to a digital press briefing on 5 March 2025.
- 13:00–14:10 The researchers will present their findings and be available for questions
- 14:15–15:00 Enzymatica's CEO, Claus Egstrand, and Chairman, Bengt Baron, will present a company overview and be available for questions
The press briefing will be broadcast live. To participate in the live discussion, please register via this link: https://creo-live.creomediamanager.com/eda7c0f6-7107-4d87-b409-82bdf2d58605
Read the press release published on 28 February here:
https://www.enzymatica.com/media/press-releases/2025/new-independent-studies-show-that-coldzyme-addresses-the-root-cause-of-respiratory-infections-reducing-sick-days-and-symptoms/
Link to the published article in The Journal of Physiology:
https://physoc.onlinelibrary.wiley.com/doi/10.1113/JP288136
For more information, contact:
Anja Tragardh, Corporate Communications, Enzymatica AB
Email: anja.tragardh@enzymatica.com
About Enzymatica
Enzymatica AB (publ) develops and markets products that treat and alleviate infections and symptoms in the upper airways. The best-selling product is ColdZyme®, an oral spray for colds and cold-like symptoms in the upper airways. The company's strategy is to continue growing by strengthening its position in existing markets and expanding into additional geographic markets through collaborations with established partners under their brands in the cold remedy market. The company is headquartered in Lund and is listed on Nasdaq First North Growth Market. The Certified Adviser is Carnegie Investment Bank AB (publ).
For more information, visit www.enzymatica.se